CD33 and acute myeloid leukemia: Albinger et al., developed CD33 CAR-NK cells that exhibited enhanced in vitro cytotoxicity against an AML cell line and primary samples and increased leukemia control in an AML xenograft model after three infusions without any identifiable toxicities [66].